[Mucosat in treatment of osteoarthritis].
Mucosat is the original and reference preparation of chondroitin sulfate with distinct antiinflammatory and hondroprotective properties used for the treatment of osteoarthritis (OA). The purpose of research is to evaluate the efficacy and tolerability of Mucosat by OA patients. The study included 49 women of average age of 52.4±7.9 years with disease duration of 8.6±5.8 years, at a body mass index of 30.5±4.8 kg/m2. Co-morbidity: previous oncopathology, diabetes, hypertension, obesity. The main symptom was joint pain VAS (100 mm) - 60.2±10.1 mm, index WOMAC pain - 220.7±84.5 mm, WOMAC stiffness - 89.3±39.5, WOMAC function - 726±229.9, WOMAC total - 1036.4±353.9 mm. Mucosat was prescribed intramuscularly. The results were assessed after 3, 8 and 12 weeks on the dynamics of pain (VAS), WOMAC index, in need for NSAID and satisfaction with treatment on a scale from 1 to 5; where '1' is the complete absence of improvement, and '5' is a great result. The control group consisted of 15 OA patients who did not receive hondroprotective treatment for 6 months prior to treatment, received 'on demand' or constantly received NSAIDs. Pain dynamics by VAS and WOMAC index was statistically reliable at 3 week, 8 week and 12 week period of research. 18% of patients stop taking NSAIDs at 3 week, 54% were taking NSAIDs 'on demand' up to 8 weeks. Excellent effect was noted by 42%, good - 22%, low - 8% of patients. Undesirable reactions and side effects were not. The study proved: Mucosat is effective and safe drug for the treatment of OA.